A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TEs
Long Form : thrombotic events
No. Year Title Co-occurring Abbreviation
2019 Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data. Hct, PV, VHA
2019 Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. MM
2019 Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). AH, aPCC, CHwI, FVII, GT, PI, rFVIIa
2018 Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. aCL, APS, eGFR, HR
2018 Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. PV
2018 Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio. INR, LVADs, MBEs
2018 [Thrombosis in multiple myeloma]. MM
2017 Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. aPTT-LA, LA, LATS, SHR
2017 Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. LDH
10  2016 Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. OS, PNH
11  2016 Left atrial appendage obliteration in atrial fibrillation patients undergoing bioprosthetic mitral valve replacement. AF, LA, LAA, MVR
12  2015 Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013. CFD, CFs
13  2015 Safety update on the use of recombinant activated factor VII in approved indications. FVII, rFVIIa
14  2015 The association between mean platelet volume and chronic atrial fibrillation and the presence of thrombotic events. AF, fL, hs-CRP, LAD, MPV
15  2015 Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. BMI, BV, mCRC
16  2014 Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. CIs, HIRD, Ig, ORs
17  2013 Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. DC, HIG
18  2013 Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. CKD, PNH
19  2013 Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. IBD
20  2012 Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. CIs, Ig, ORs
21  2011 Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. ---
22  2005 Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. ACLAs, anti-beta2GPI, anti-PT, APLA, LAs, SLE
23  2003 A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. ALL, ASP
24  2001 Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. ACLAs, APCR, APLAs, LAs, SLE
25  2001 [Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus]. APCR, APLAs, dRVVT-LA, SLE